CD8A and neoplasm: In addition, NP-APC11 treatment, in contrast to NP-APC11M treatment, significantly increased the expression of the effector cytokines IFNγ and TNFα in CD8+ T cells, highlighting its role in enhancing the anti-tumor immune response (Fig. 7i).